Difference between revisions of "Team:Queens Canada/Description"
(11 intermediate revisions by the same user not shown) | |||
Line 11: | Line 11: | ||
<div id="navbar"> | <div id="navbar"> | ||
− | + | <nav id="qgemnav"> | |
<ul> | <ul> | ||
<li><a href="https://2015.igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2015/f/fa/Qqq_IGEM_official_logo.png" /></a></li> | <li><a href="https://2015.igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2015/f/fa/Qqq_IGEM_official_logo.png" /></a></li> | ||
Line 24: | Line 24: | ||
</ul> | </ul> | ||
+ | |||
</li> | </li> | ||
<li><a href="https://2015.igem.org/Team:Queens_Canada/Notebook">Notebook</a></li> | <li><a href="https://2015.igem.org/Team:Queens_Canada/Notebook">Notebook</a></li> | ||
Line 31: | Line 32: | ||
<li><a href="https://2015.igem.org/Team:Queens_Canada/Background">Background</a></li> | <li><a href="https://2015.igem.org/Team:Queens_Canada/Background">Background</a></li> | ||
<li><a href="https://2015.igem.org/Team:Queens_Canada/Modeling">Modeling</a></li> | <li><a href="https://2015.igem.org/Team:Queens_Canada/Modeling">Modeling</a></li> | ||
− | <li><a href="https://2015.igem.org/Team:Queens_Canada/AFP_Scaffold"> | + | <li><a href="https://2015.igem.org/Team:Queens_Canada/AFP_Scaffold"> The Ice Queen</a></li> |
− | <li><a href="https://2015.igem.org/Team:Queens_Canada/Circ_AFP"> | + | <li><a href="https://2015.igem.org/Team:Queens_Canada/Circ_AFP"> Icefinity</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Line 49: | Line 50: | ||
<div id="motivation" style="padding: 60px 200px 20px 200px;"> | <div id="motivation" style="padding: 60px 200px 20px 200px;"> | ||
− | <h1> | + | <h1>PROJECT OVERVIEW</h1> |
+ | <p align="center"><em>Take a look at our <a href="#judgingcrit">Judging Criteria</a> below!</em></p> | ||
<h2>Motivation</h2> | <h2>Motivation</h2> | ||
Line 55: | Line 57: | ||
<p>The demand for organs for transplantation has been steadily increasing as waiting lists become longer and longer. Over 1600 Canadians are added to the organ wait list every year.<sup>1</sup> Figure 1 illustrates how over the years the gap between the number of people on organ wait lists and the number of donors has been steadily increasing.</p> | <p>The demand for organs for transplantation has been steadily increasing as waiting lists become longer and longer. Over 1600 Canadians are added to the organ wait list every year.<sup>1</sup> Figure 1 illustrates how over the years the gap between the number of people on organ wait lists and the number of donors has been steadily increasing.</p> | ||
<figure style="width: 600px; margin-left: auto; margin-right: auto;"> | <figure style="width: 600px; margin-left: auto; margin-right: auto;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/b/ba/Qqq_QGEM_gapgraph.jpg" /> |
<figcaption>Figure 1.<strong>Number of people waiting for an organ in relation to number of donors and transplants performed over time.</strong>Data taken from the US Department of Health and Human Services and numbers are for the USA only.<sup>2</sup> **Data includes deceased and living donors.</figcaption> | <figcaption>Figure 1.<strong>Number of people waiting for an organ in relation to number of donors and transplants performed over time.</strong>Data taken from the US Department of Health and Human Services and numbers are for the USA only.<sup>2</sup> **Data includes deceased and living donors.</figcaption> | ||
</figure> | </figure> | ||
<p>However, organ shortage appears to only to be one of the challenges to transplant medicine. To effectively tackle this problem, we had to understand the full picture. Along with the increasing demand for organs, we also face inadequate organ preservation methods, limiting the amount of time an organ can be stored for transplantation. This creates a very small window of time for officials to find a compatible recipient for the organ.<sup>3</sup> Because of this limiting timespan, organ rejection and incompatibility generates another large problem in the organ transplant field. This leads to the loss of a significant number of organs that become non-viable after harvest.</p> | <p>However, organ shortage appears to only to be one of the challenges to transplant medicine. To effectively tackle this problem, we had to understand the full picture. Along with the increasing demand for organs, we also face inadequate organ preservation methods, limiting the amount of time an organ can be stored for transplantation. This creates a very small window of time for officials to find a compatible recipient for the organ.<sup>3</sup> Because of this limiting timespan, organ rejection and incompatibility generates another large problem in the organ transplant field. This leads to the loss of a significant number of organs that become non-viable after harvest.</p> | ||
<figure style="width: 300px; float: right;"> | <figure style="width: 300px; float: right;"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2015/6/67/Qqq_QGEM_UWsoln.png" style="width: 300px;" /> |
<figcaption>The image above from the Wisconsin State Journal shows a surgical coordinator storing an organ on ice with a perfusion pump containing UW solution.<sup>4</sup></figcaption> | <figcaption>The image above from the Wisconsin State Journal shows a surgical coordinator storing an organ on ice with a perfusion pump containing UW solution.<sup>4</sup></figcaption> | ||
</figure> | </figure> | ||
Line 75: | Line 77: | ||
<h2>Icefinity</h2> | <h2>Icefinity</h2> | ||
<p>As an addition to our project this year, we decided to further explore the topic of AFPs and their variety of applications. Protein stability is of great importance when considering the use of AFPs in industry. Typical industrial processes often involve harsh conditions which will lead to denaturation (i.e. loss of function) for the protein. Therefore, in conjunction with improving the activity of the Type III AFP, we set out to increase the stability of the protein through circularization techniques.</p> | <p>As an addition to our project this year, we decided to further explore the topic of AFPs and their variety of applications. Protein stability is of great importance when considering the use of AFPs in industry. Typical industrial processes often involve harsh conditions which will lead to denaturation (i.e. loss of function) for the protein. Therefore, in conjunction with improving the activity of the Type III AFP, we set out to increase the stability of the protein through circularization techniques.</p> | ||
− | <p>Using Heidelberg’s intein biobrick <a href="http://parts.igem.org/Part:BBa_K1362000">BBa_K1362000</a>, we performed the intein-splicing reaction with the AFP to generate a circular protein: Icefinity. Heidelberg and other research parties have shown an increase in thermostability after cyclizing any protein.<sup>8, 9</sup> This summer, Circularization of the AFP has been a wonderful addition to our exploration of this fascinating protein. It also gave us the chance to make use of the open source iGEM registry and even improve upon Heidelberg’s construct. Read about our results <a href=" | + | <p>Using Heidelberg’s intein biobrick <a href="http://parts.igem.org/Part:BBa_K1362000">BBa_K1362000</a>, we performed the intein-splicing reaction with the AFP to generate a circular protein: Icefinity. Heidelberg and other research parties have shown an increase in thermostability after cyclizing any protein.<sup>8, 9</sup> This summer, Circularization of the AFP has been a wonderful addition to our exploration of this fascinating protein. It also gave us the chance to make use of the open source iGEM registry and even improve upon Heidelberg’s construct. Read about our results <a href="https://2015.igem.org/Team:Queens_Canada/Circ_AFP">here!</a> </p> |
− | <p>The QGEM team worked to develop Heidelberg’s intein biobrick by adding a T7 promoter to our submitted circular AFP construct. Inserting a promoter allows our biobrick to not only be a carrier, but also be an expression construct of our circular AFP. This biobrick part <a href=" | + | <p>The QGEM team worked to develop Heidelberg’s intein biobrick by adding a T7 promoter to our submitted circular AFP construct. Inserting a promoter allows our biobrick to not only be a carrier, but also be an expression construct of our circular AFP. This biobrick part <a href="http://parts.igem.org/Part:BBa_K1831000">BBa_K1831000</a> is described in more detail on our <a href="https://2015.igem.org/Team:Queens_Canada/Parts">Parts Page</a> and the iGEM registry.</p> |
− | <h1> | + | <h1>REFERENCES</h1> |
<p>1. Canadian Transplant Society. (2014).</p> | <p>1. Canadian Transplant Society. (2014).</p> | ||
<p>2. "US Government Information on Organ and Tissue Donation and Transplantation". (2012). US Department of Health & Human Services.</p> | <p>2. "US Government Information on Organ and Tissue Donation and Transplantation". (2012). US Department of Health & Human Services.</p> | ||
Line 91: | Line 93: | ||
<div id="judgingcrit" style="padding: 60px 300px 20px 300px;"> | <div id="judgingcrit" style="padding: 60px 300px 20px 300px;"> | ||
− | <h1> | + | <h1>JUDGING CRITERIA</h1> |
<h2 style="color: #965A38;">Bronze</h2> | <h2 style="color: #965A38;">Bronze</h2> | ||
<ul> | <ul> | ||
− | <li>A list of acknowledgements can be found on our <a href=" | + | <li>A list of acknowledgements can be found on our <a href="https://2015.igem.org/Team:Queens_Canada/Attributtions">Attributions page</a>, and our generous sponsors are described on our <a href="https://2015.igem.org/Team:Queens_Canada/Sponsorship">Sponsorship page</a>. </li> |
− | <li>Our <a href=" | + | <li>Our <a href="https://2015.igem.org/Team:Queens_Canada/Parts">Parts page</a> describes 4 new biobrick parts that have also been submitted to the registry.</li> |
</ul> | </ul> | ||
<h2 style="color: #A8A8A8;">Silver</h2> | <h2 style="color: #A8A8A8;">Silver</h2> | ||
<ul> | <ul> | ||
− | <li>We have experimentally validated the expression of our circularized AFP and AFP-Ecoil BioBricks: | + | <li>We have experimentally validated the expression of our circularized AFP and AFP-Ecoil BioBricks: BBa_K1831000 and BBa_K1831002. Both these parts have been submitted to the registry</li> |
− | <li>One of our Human Practices activities this summer was focused on exploring the intellectual property (IP) and patenting process for the Ice Queen. We looked into the feasibility of patenting our AFP-Scaffold complex; during our investigation we also learned a lot about the benefits and limitations of patenting IP. Read more about it <a href=" | + | <li>One of our Human Practices activities this summer was focused on exploring the intellectual property (IP) and patenting process for the Ice Queen. We looked into the feasibility of patenting our AFP-Scaffold complex; during our investigation we also learned a lot about the benefits and limitations of patenting IP. Read more about it <a href="https://2015.igem.org/Team:Queens_Canada/Practices/IP">here</a>.</li> |
</ul> | </ul> | ||
<h2 style="color: #C98910;">Gold</h2> | <h2 style="color: #C98910;">Gold</h2> | ||
<ul> | <ul> | ||
− | <li>We have improved the characterization of the Calgary 2013 Team's BioBricks; <a href=" | + | <li>We have improved the characterization of the Calgary 2013 Team's BioBricks; <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189010">Bba_K1189010</a> and <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189011">Bba_K1189011</a>. </li> |
− | <li>We also integrated the theme of education throughout our Human Practices Project; we organized a workshop for SHAD valley students, gave a public seminar on the applications our project, and participated in course development work. Take a look at our <a href=" | + | <li>We also used Heidelberg's intein BioBrick for our own purposes, improving upon its design by adding a T7 promoter to our BioBrick, allowing for direct expression of the protein without any subcloning.</a></li> |
+ | <li>We also integrated the theme of education throughout our Human Practices Project; we organized a workshop for SHAD valley students, gave a public seminar on the applications our project, and participated in course development work. Take a look at our <a href="https://2015.igem.org/Team:Queens_Canada/Practices">Human Practices</a> page! </li> | ||
</ul> | </ul> | ||
Latest revision as of 13:42, 18 September 2015